Feb 04, 2021
Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla®
Dec 18, 2020
Slayback Pharma announces FDA approval of Merzee, generic equivalent of Taytulla® with a Competitive Generic Therapy (CGT) Designation
Jan 06, 2020
Slayback Pharma announces investment of $50 million by The Everstone Group
Dec 10, 2019
Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex(TM) 4 mcg/ mL
Mar 25, 2019
Slayback Pharma announces approval of Hydroxyprogesterone Caproate Injection, USP 250 mg/ 1 mL in a single-dose vial, generic equivalent of Makena® Injection 250 mg/ 1 mL
Jan 21, 2019
Slayback Pharma announces launch of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena® Injection 1,250 mg/ 5 mL multi-dose vial
Jan 02, 2019
Slayback Pharma announces FDA approval of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena® Injection 1,250 mg/ 5 mL multi-dose vial
Jul 24, 2018
Slayback Pharma Appoints Dr Girish Jain as Head of Global R&D
Jul 16, 2018
Slayback Pharma Appoints Joan Janulis as Head of Global Regulatory Affairs
Jun 29, 2018
Ajay Singh of Slayback Pharma wins Ernst and Young's Entrepreneur Of The Year® 2018 Award in Life Sciences Category in New Jersey